Dergiler / Recent Trends in Pharmacology / 2023 / Cilt: 1 Sayı: 2

General Aspect of the Assessment and Management of the Poisonous Mushrooms in Turkiye

Sayfa
92–109
Yayın Tarihi
2023-08-29
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Specific treatment approaches should be applied according to mushrom species.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Patients who exposed with poisonous mushrooms may apply to emergency services with a serious clinical conditions ranging from simple gastrointestinal complaints to liver failure.
📊
Temel Bulgular & Veri:Poisonings are typically classified as acute onset (<6 hour), late onset (6-24 hours) and delayed onset (>1 day) toxicity.
💡
Sonuç & Katkı:Specific treatment approaches should be applied according to mushrom species.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Mushroom poisoning · Acute onset · Late onset

Abstract

Patients who exposed with poisonous mushrooms may apply to emergency services with a serious clinical conditions ranging from simple gastrointestinal complaints to liver failure. The clinical findings of mushroom poisoning differ according to the toxin of the mushroom species consumed. Poisonings are typically classified as acute onset (<6 hour), late onset (6-24 hours) and delayed onset (>1 day) toxicity. Acute onset mushroom poisonings occure within 6 hours after consuming the mushroom and cause cholinergic toxicity, gastrontestinal findings, disulfiram like reaction, seizures and hallucinations. Late onset mushroom poisonings occure within 6-24 hours with the hepatotoxicity, nephrotoxicity and erythromelalgia. Delayed onset mushroom poisonings occure after 1 day of consuming mushroom with nephrotoxicity, neurotoxicity and rhabdomyolysis. While the prognosis is good in case of early onset of symptoms in mushroom poisoning, the prognosis is poor in case of late onset of symptoms. Most mushroom poisonings that cause gastrointestinal symptoms improve with adequate supportive treatment. Hepatotoxic mushrooms containing cyclopeptide are largely responsible for deaths due to mushroom poisonings. In all cases, basic laboratory evaluation and symptomatic supportive treatment approach are required. There are no antidotes with proven efficacy in the treatment of mushroom poisoning. Specific treatment approaches should be applied according to mushrom species.

🔖

Bu Makaleye Atıf Yap

ŞAHİN, A., ARİCİ, A., KORKUT, S., TUNÇOK, Y. (2023). General Aspect of the Assessment and Management of the Poisonous Mushrooms in Turkiye. Recent Trends in Pharmacology, Cilt: 1 Sayı: 2, 92–109. https://ajindex.com/articles/1016086

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Akata, I. (2017). Poisonous Mushrooms of Turkey. January. Altintepe, L., Yazici, R., Yazici, M., Solak, Y., Topal, M., Isik, A., & Guney, I. (2014). Temporary left ventricular dysfunction in mushroom poisoning: Report of three cases. Renal Failure, 36(8), 1337–1339. https://doi.org/10.3109/0886022X.2014.930649
  2. Arici, M. A., Sahin, A., Cavdar, Z., Ergur, B. U., Ural, C., Akokay, P., Kalkan, S., & Tuncok, Y. (2020). Effects of resveratrol on alpha-amanitin-induced nephrotoxicity in BALB/c mice. Human and Experimental Toxicology, 39(3), 328–337. https://doi.org/10.1177/0960327119888271
  3. Arıcı A, T. Y. (2021). Mushroom-related toxins, alpha amanitin, and usage of antioxidants: Directions toward antioxidant capacity. In Oxidative Stress and Dietary Antioxidants (pp. 447–456). Arłukowicz-Grabowska, M., Wójcicki, M., Raszeja-Wyszomirska, J., Szydłowska-Jakimiuk, M., Piotuch, B., & Milkiewicz, P. (2019). Acute liver injury, acute liver failure and acute on chronic liver failure: A clinical spectrum of poisoning due to Gyromitra esculenta. Annals of Hepatology, 18(3), 514–516. https://doi.org/10.1016/j.aohep.2018.11.009
  4. Borowiak, K. S., Ciechanowski, K., & Waloszczyk, P. (1998). ) Intoxication with Myocardial Infarction. Clinical Toxicology, 36, 47–49.
  5. Cho, J. T., & Han, J. H. (2016). A case of mushroom poisoning with Russula subnigricans: Development of rhabdomyolysis, acute kidney injury, cardiogenic shock, and death. Journal of Korean Medical Science, 31(7), 1164–1167. https://doi.org/10.3346/jkms.2016.31.7.1164 Clinical toxicology, 30(. (1992). 30, 13–22.
  6. Colak, S., Kandis, H., Afacan, M. A., Erdogan, M. O., Gunes, H., Kaya, E., Akdemir, H. U., & Saritas, A. (2015). Assessment of patients who presented to the emergency department with mushroom poisoning. Human and Experimental Toxicology, 34(7), 725–731. https://doi.org/10.1177/0960327114557902
  7. Colomer-Carbonell, A., Sanabria-Mazo, J. P., Hernández-Negrín, H., Borràs, X., Suso-Ribera, C., Garciá-Palacios, A., Muchart, J., Munuera, J., D’Amico, F., Maes, M., Younger, J. W., Feliu-Soler, A., Rozadilla-Sacanell, A., & Luciano, J. V. (2022). Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). BMJ Open, 12(1). https://doi.org/10.1136/bmjopen-2021-055351
  8. Diaz, J. H. (2005). Syndromic diagnosis and management of confirmed mushroom poisonings.